Cardinal Health (CAH)
(Delayed Data from NYSE)
$111.93 USD
-0.62 (-0.55%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $111.94 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.93 USD
-0.62 (-0.55%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $111.94 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Zacks News
3 MedTech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Cardinal Health (CAH) to Build Distribution Center in Greenville
by Zacks Equity Research
Cardinal Health's (CAH) new facility will be its largest at-Home Solutions distribution center that will support business growth by providing new space and automation.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights McDonald's, W.W. Grainger and Cardinal Health
by Zacks Equity Research
McDonald's, W.W. Grainger and Cardinal Health are included in this Analyst Blog.
3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
3 Top S&P 500 Stocks to Buy as Index Tastes 4200 Mark
by Tirthankar Chakraborty
Banking on recent strengths, investors should place their bets on sound stocks like McDonald's (MCD), W.W. Grainger (GWW) & Cardinal Health (CAH) that are poised to scale upward along with the broader S&P 500 Index.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Alcon (ALC) Vision Care Sales Robust, Margin Pressure Persists
by Zacks Equity Research
For Alcon (ALC), in terms of end market, Surgical global cataract procedure growth varies significantly by region.
Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod
by Zacks Equity Research
Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) on strategic partnerships and upbeat guidance.
Zacks.com featured highlights include Cardinal Health, Boyd Gaming, Ford Motor, NXP Semiconductors N.V and American International
by Zacks Equity Research
Cardinal Health, Boyd Gaming, Ford Motor, NXP Semiconductors N.V and American International are part of the Zacks Screen of the Week article.
Abbott's (ABT) New Pact to Advance Clinical Trials Diversity
by Zacks Equity Research
Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.
Here's Why You Should Retain Veeva Systems (VEEV) Stock Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
Here's Why You Should Retain Veradigm (MDRX) Stock for Now
by Zacks Equity Research
Veradigm (MDRX) continues to hold on to investors' interests owing to its strategic alliances.
5 Attractive Value Picks Based on Discounted PEG
by Urmimala Biswas
Here are five stocks that meet our screening criteria - CAH, BYD, F, NXPI, AIG.
National Vision (EYE) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
National Vision's (EYE) Q1 net revenues are positively impacted by the timing of unearned revenue.
Here's Why You Should Retain Patterson Companies (PDCO) Stock Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
Why You Should Buy The Cooper Companies (COO) Stock Now
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
NextGen (NXGN) Behavioral Health Suite to Focus on Mental Health
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to offer better access to care and improve patient outcomes.
Revvity's (PKI) Q1 Earnings Top, '23 View Below Expectations
by Zacks Equity Research
Revvity's (PKI) first-quarter results reflect the impact of transition following divestment of AES business. While earnings outpace estimates, sales miss the same.